Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/33140

Type
Article
Copyright
Open access
Embargo date
2019-11-20
Collections
Share

Statistics
Metadata
Show full item record

IN VITRO ANTIFUNGAL SUSCEPTIBILITY OF CRYPTOCOCCUS GATTII
Trilles, L. et al. | Date Issued: 2004
Author
Trilles, L.
Torres, B. F.
Lazéra, M. S.
Wanke, B.
Guarro, J.
Affilliation
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Serviço de Micologia Médica. Rio de Janeiro, RJ, Brasil.
Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut. Unitat de Microbiologia. Reus, Spain.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Serviço de Micologia Médica. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Serviço de Micologia Médica. Rio de Janeiro, RJ, Brasil.
Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut. Unitat de Microbiologia. Reus, Spain.
Abstract
We have determined the in vitro susceptibilities of 57 strains of Cryptococcus gattii to nine antifungal agents and have compared the MICs for these strains with those for C. neoformans. MICs were determined by a microdilution reference method. Albaconazole and ravuconazole (MICs of 0.04 and 0.05 µg/ml, respectively) showed the best activities. Micafungin showed no activity (MIC of >128 µg/ml). In general, C. gattii was less susceptible than C. neoformans to all drugs tested, with the exception of amphotericin B and flucytosine.
Keywords
Cryptococcus gattii
In vitro susceptibilities
 
Publisher
American Society for Microbiology
Citation
TRILLES, Luciana et al. In vitro antifungal susceptibility of Cryptococcus gattii. Journal of Clinical Microbiology, v. 42, n. 10, p. 4815-4817, Oct. 2004.
DOI
10.1128/JCM.42.10.4815–4817.2004
ISSN
0095-1137